NLS Pharmaceutics Ltd (NLSP)
0.1494
0.00 (0.00%)
USD |
NASDAQ |
May 16, 16:00
0.1692
+0.02
(+13.25%)
After-Hours: 05:59
NLS Pharmaceutics Shareholders Equity (Quarterly): -4.287M for June 30, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
June 30, 2023 | -4.287M |
June 30, 2023 | -4.287M |
December 31, 2022 | 3.281M |
June 30, 2022 | -4.042M |
June 30, 2022 | -4.042M |
December 31, 2021 | 0.5424M |
June 30, 2021 | 4.249M |
June 30, 2021 | 4.249M |
Date | Value |
---|---|
December 31, 2020 | -8.984M |
June 30, 2020 | -7.334M |
June 30, 2020 | -7.334M |
December 31, 2019 | -6.171M |
June 30, 2019 | -4.197M |
June 30, 2019 | -4.197M |
December 31, 2018 | -8.814M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-8.984M
Minimum
Dec 2020
4.249M
Maximum
Jun 2021
-3.039M
Average
-4.197M
Median
Jun 2019
Shareholders Equity (Quarterly) Benchmarks
AC Immune SA | 160.35M |
CRISPR Therapeutics AG | 2.084B |
Addex Therapeutics Ltd | 1.364M |
Molecular Partners AG | 210.05M |
MoonLake Immunotherapeutics | 542.55M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 2.270M |
Total Liabilities (Quarterly) | 6.557M |